Lockheed Martin Investment Management Co. acquired a new stake in Celgene Corporation (NASDAQ:CELG) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,299,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Neuberger Berman Group LLC increased its stake in shares of Celgene Corporation by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares in the last quarter. Lincoln Capital Corp boosted its holdings in Celgene Corporation by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares during the last quarter. Swiss National Bank boosted its holdings in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Celgene Corporation by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares during the last quarter. Finally, Boston Partners boosted its holdings in Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares during the last quarter. 79.33% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Lockheed Martin Investment Management Co. Acquires New Stake in Celgene Corporation (CELG)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/lockheed-martin-investment-management-co-acquires-new-stake-in-celgene-corporation-celg/1588086.html.

Several equities analysts recently issued reports on CELG shares. Mizuho raised their price target on Celgene Corporation from $130.00 to $134.00 and gave the company a “buy” rating in a report on Thursday, June 1st. Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Tuesday, June 6th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $148.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, June 8th. Finally, BidaskClub upgraded Celgene Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $149.34.

Shares of Celgene Corporation (CELG) opened at 144.94 on Tuesday. The stock’s 50 day moving average price is $135.45 and its 200-day moving average price is $127.81. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $146.13. The company has a market capitalization of $113.39 billion, a P/E ratio of 44.89 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the company earned $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.

In related news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 44,506 shares of company stock valued at $6,019,761 over the last ninety days. Corporate insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.